AmplifyBio Acquires PACT Pharma to Advance Cell and Gene Therapy Services
4 October 2022
Collaborations, Mergers & Acquisitions
Finance & Investment
The contract and research organization (CRO) AmplifyBio has announced the acquisition of select assets from privately held biopharmaceutical company PACT Pharma Inc to advance its cell and gene therapy service offerings.
This acquisition will see AmplifyBio gain access to agreed asset purchases of PACT Pharma’s advanced characterization platforms and bioinformatics capabilities, as well as an expert drug development workforce of 40 personnel and PACT’s San Francisco advanced laboratory space, to accelerate innovation across pharmaceutical modalities.
“Our acquisition of these assets from PACT Pharma means that cell and gene therapies can now be differentiated based on safety and efficacy profiles and specific product characteristics, not development processes,” says J. Kelly Ganjei, AmplifyBio CEO and President.
There is currently a lack of consistency in therapeutic characterization, with no single universal process for companies researching, developing, and testing cell and gene therapeutics.
The inconsistency in these discoveries to preclinical testing processes can result in the need for material changes during later developmental stages. Any alterations in therapeutic production can impact manufacturing consistencies and cause safety concerns when it comes to scale-up.
AmplifyBio’s partnership with PACT Pharma will see them work towards providing an early and consistent characterization of the purity, potency, and viability of treatment throughout its therapeutic development life cycle.
“This deal allows PACT to retain its core intellectual property and continue our mission of developing novel, neoantigen-targeted T-Cell Therapies,” says Scott Garland, PACT Pharma CEO. “At the same time, we’re working with AmplifyBio to leverage our platforms to offer a unique combination of optimization, characterization, safety, and efficacy services to a wider range of clients seeking to better understand the immunology of their adoptive cell therapies,” he adds.
Following the acquisition of PACT’S South San Francisco laboratory under the announced agreement, AmplifyBio also plan to extend its facilities further by building another site in New Albany Ohio.
The proposed 350,000 square feet of multi-functional lab space will provide the Company with the capabilities for complex genotypic and phenotypic characterization analysis in late-stage development.
AmplifyBio has also communicated the expectation to secure future partnerships and developmental platforms to enhance its commercial acceleration to deliver safe, effective, and reproducible cell and gene therapies.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.